Silencing of NRF2 also suppressed CSCs markers in breast cancer model [133] in ALDH-high ovarian cancer cells [134], and sorafenib-resistant hepatocellular carcinoma cells [135]. Here, NFE2L2 is linked to breast carcinoma.